静脉血栓栓塞症预防市场 - 全球产业规模、份额、趋势、机会和预测，按类型、最终用途、地区和竞争细分，2020-2030 年预测

2024 年全球静脉血栓栓塞症预防市场价值为 68.2 亿美元，预计到 2030 年将达到 94.6 亿美元，复合年增长率为 5.58%。预计到 2030 年将达到 94.6 亿美元，复合年增长率为 5.58%。人们对未经治疗的 VTE 相关併发症的认识不断提高，导致人们广泛采用预防措施，包括抗凝血剂等药物干预和压迫装置等机械方法。医疗保健基础设施的扩展和诊断技术的进步使得早期发现和治疗高风险患者成为可能。医院和门诊护理机构对病人安全协议的日益重视进一步推动了 VTE 预防的采用。人工智慧（AI）和预测分析在识别高风险个体方面的整合正在改善治疗结果并优化资源分配。

癌症、心血管疾病和肥胖等慢性疾病的发生率不断上升，导致对有效 VTE 预防治疗的需求不断增加。直接口服抗凝血剂 (DOAC) 作为传统抗凝血剂的更安全、更方便的替代品，越来越受到人们的青睐。向门诊护理和微创手术的转变加速了对医院以外预防措施的需求。间歇性气动压缩 (IPC) 系统和渐进式压力袜等机械预防设备的技术进步正在提高患者的依从性和治疗效果。促进血栓预防的医疗政策和报销计划正在加强市场成长。预计生物製剂和下一代抗凝血剂研究的不断加强将引入创新的治疗方案，降低出血风险，同时确保有效预防血栓。老年人口的不断增长，使人们更容易感染静脉血栓栓塞症 (VTE)，这为预防性治疗带来了巨大的成长潜力。

发展中地区对 VTE 预防的认识和可近性有限仍然是市场扩张的重大障碍。新型抗凝血疗法和机械装置的高成本限制了人们的负担能力，尤其是对于低收入者而言。由于担心出血风险和抗凝血剂的潜在副作用而导致患者犹豫，从而影响采用率。新药和新设备的严格监管审批流程导致产品进入市场的延迟，从而限制了先进预防治疗方案的可用性。某些医疗机构未遵守 VTE 预防指南，导致预防策略实施不一致。管理患有多种合併症的患者的 VTE 风险的复杂性给医疗保健提供者带来了额外的挑战。透过有针对性的宣传计划、具成本效益的治疗方案和简化的监管途径解决这些障碍对于全球静脉血栓栓塞症预防市场持续成长至关重要。

主要市场驱动因素

人口老化

主要市场挑战

预防费用

主要市场趋势

数位健康整合

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球静脉血栓栓塞症预防市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（下肢、上肢）
  • 依最终用途（医院和诊所、门诊护理中心、其他）
  • 按公司分类（2024）
• 市场地图
  • 按类型
  • 按最终用途
  • 按地区

第 5 章：亚太地区静脉血栓栓塞症预防市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型
  • 按最终用途
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 6 章：欧洲静脉血栓栓塞症预防市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美静脉血栓栓塞症预防市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲静脉血栓栓塞症预防市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲静脉血栓栓塞症预防市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球静脉血栓栓塞症预防市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Arjo
• Encompass Group
• Argon Medical Devices
• MEGO AFEK
• Zenith Technical Innovations
• Cook Medical
• Bio Compression Systems
• ThermoTek USA
• Boston Scientific Corporation
• Cardinal Health (Medtronic)

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Venous Thromboembolism Prophylaxis Market was valued at USD 6.82 Billion in 2024 and is expected to reach USD 9.46 Billion in the forecast period with a CAGR of 5.58% through 2030. The Global Venous Thromboembolism (VTE) Prophylaxis Market is witnessing steady growth due to the rising incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), which pose significant health risks, particularly among hospitalized and post-surgical patients. Increased awareness of the complications associated with untreated VTE has led to the widespread adoption of prophylactic measures, including pharmacological interventions such as anticoagulants and mechanical methods like compression devices. The expansion of healthcare infrastructure and advancements in diagnostic technologies are enabling early detection and treatment of at-risk patients. Growing emphasis on patient safety protocols in hospitals and ambulatory care settings is further driving the adoption of VTE prophylaxis. The integration of artificial intelligence (AI) and predictive analytics in identifying high-risk individuals is improving treatment outcomes and optimizing resource allocation.

Increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and obesity is contributing to the rising demand for effective VTE prophylaxis. The adoption of direct oral anticoagulants (DOACs) as a safer and more convenient alternative to traditional anticoagulants is gaining traction. The shift towards outpatient care and minimally invasive surgeries is accelerating the need for preventive measures beyond hospital settings. Technological advancements in mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) systems and graduated compression stockings, are improving patient compliance and outcomes. Healthcare policies and reimbursement programs promoting thromboprophylaxis are strengthening market growth. Increasing research in biologics and next-generation anticoagulants is expected to introduce innovative treatment options, reducing bleeding risks while ensuring effective clot prevention. The rising geriatric population, which is more susceptible to VTE, presents significant growth potential for prophylactic therapies.

Limited awareness and accessibility of VTE prophylaxis in developing regions remain significant barriers to market expansion. High costs associated with novel anticoagulant therapies and mechanical devices restrict affordability, particularly in low-income populations. Patient hesitation due to concerns about bleeding risks and potential side effects of anticoagulants affects adoption rates. Stringent regulatory approval processes for new drugs and devices lead to delays in market entry, limiting the availability of advanced prophylactic options. The lack of adherence to VTE prevention guidelines in certain healthcare facilities results in inconsistent implementation of prophylaxis strategies. The complexity of managing VTE risks in patients with multiple comorbidities poses additional challenges for healthcare providers. Addressing these barriers through targeted awareness programs, cost-effective treatment solutions, and streamlined regulatory pathways will be crucial for the sustained growth of the Global Venous Thromboembolism Prophylaxis Market.

Key Market Drivers

Aging Population

The aging population is a significant driving force behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. As the global population continues to age, there is a marked increase in the incidence of VTE-related health issues, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Elderly individuals are particularly vulnerable to VTE due to factors like reduced mobility, comorbidities, and alterations in blood composition. This demographic shift has led to a heightened demand for effective VTE prophylactic measures.

One primary reason for this increased demand is the higher prevalence of surgical procedures among older individuals. Surgical interventions, especially orthopedic and major surgeries, are known risk factors for VTE. The elderly population frequently undergoes joint replacements, cardiac surgeries, and other medical interventions, increasing their risk. Healthcare providers are acutely aware of this risk and are increasingly implementing prophylactic strategies, such as anticoagulant medications and mechanical devices, to minimize the likelihood of VTE in their elderly patients.

Furthermore, the elderly population's vulnerability to VTE is exacerbated by decreased mobility and lifestyle changes. Reduced physical activity and prolonged periods of immobility, such as extended bed rest or long flights, can significantly elevate the risk of blood clots. As the aging population seeks to maintain their mobility and quality of life, the demand for VTE prophylaxis becomes even more critical.

Pharmaceutical companies have responded to this growing need by developing anticoagulant medications with improved safety profiles and dosing regimens suitable for older patients. Additionally, medical device manufacturers have introduced more comfortable and efficient mechanical prophylaxis devices, ensuring that VTE prevention options are well-suited for elderly individuals.

Key Market Challenges

Cost of Prophylaxis

The price tag associated with VTE prevention, especially in the case of anticoagulant medications and mechanical devices, can be overwhelming for both healthcare systems and patients. This becomes particularly evident in regions with limited healthcare budgets or in countries where out-of-pocket expenses for medical treatments are high. Such expenses can deter individuals from seeking prophylactic measures, even when they are at risk of developing VTE.

Anticoagulant medications, while effective, often come with a high cost, especially the newer, more advanced drugs with better safety profiles and fewer side effects. For many patients, these medications need to be taken long-term, leading to escalating costs over time. Additionally, mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) pumps or advanced compression stockings, can also be pricey. While these devices are vital for patients who cannot take anticoagulants due to contraindications, their costs can be a significant barrier to widespread adoption.

Furthermore, the financial implications of VTE prophylaxis are not limited to the direct cost of medications and devices. Monitoring patients, especially those on anticoagulant medications, requires regular blood tests and follow-ups, incurring additional expenses. For many patients, especially those without comprehensive insurance coverage, these cumulative costs can be daunting.

Key Market Trends

Digital Health Integration

Digital health integration is emerging as a pivotal driver behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), affects up to 900,000 Americans annually, with an estimated 60,000 to 100,000 deaths each year. The integration of digital health technologies is revolutionizing VTE prophylaxis management, leading to more effective prevention and improved patient outcomes.

Electronic health records (EHRs) serve as a cornerstone in this integration, enabling healthcare providers to swiftly access patient histories, risk factors, and medication profiles. This real-time data access facilitates timely risk assessments, ensuring high-risk patients receive appropriate prophylactic measures. Studies have shown that implementing EHRs can reduce medication errors by 54% and adverse drug reactions by 36%, thereby enhancing patient safety.

Remote patient monitoring systems also play a vital role in enhancing VTE prevention. These systems allow continuous monitoring of patients post-discharge, tracking activity levels, vital signs, and medication adherence. Such surveillance is crucial, as more than one-third of VTE cases are associated with recent hospitalizations, with many events occurring after discharge. By detecting early warning signs of VTE development, healthcare teams can intervene promptly, significantly reducing incidence rates and improving patient safety.

Telemedicine platforms further contribute to VTE prophylaxis by facilitating virtual consultations, enabling healthcare providers to assess risk factors and guide prophylactic measures remotely. This approach is particularly beneficial given that as many as 70% of healthcare-associated VTE cases are preventable through measures such as anticoagulant medications or compression stockings. Remote consultations enhance patient education and engagement, promoting adherence to preventive strategies.

Key Market Players

• Arjo
• Encompass Group
• Argon Medical Devices
• MEGO AFEK
• Zenith Technical Innovations
• Cook Medical
• Bio Compression Systems
• ThermoTek USA
• Boston Scientific Corporation
• Cardinal Health (Medtronic)

Report Scope:

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Venous Thromboembolism Prophylaxis Market, By Type:

• Lower Extremity
• Upper Extremity

Venous Thromboembolism Prophylaxis Market, By End Use:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Venous Thromboembolism Prophylaxis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.

Available Customizations:

Global Venous Thromboembolism Prophylaxis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Venous Thromboembolism Prophylaxis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Lower Extremity, Upper Extremity)
  • 4.2.2. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.3. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By End Use
  • 4.3.3. By Region

5. Asia Pacific Venous Thromboembolism Prophylaxis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By End Use
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By End Use
  • 5.3.2. India Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By End Use
  • 5.3.3. Australia Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By End Use
  • 5.3.4. Japan Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By End Use
  • 5.3.5. South Korea Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By End Use

6. Europe Venous Thromboembolism Prophylaxis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By End Use
  • 6.3.2. Germany Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By End Use
  • 6.3.3. Spain Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By End Use
  • 6.3.4. Italy Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By End Use
  • 6.3.5. United Kingdom Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By End Use

7. North America Venous Thromboembolism Prophylaxis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Venous Thromboembolism Prophylaxis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By End Use
  • 7.3.2. Mexico Venous Thromboembolism Prophylaxis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By End Use
  • 7.3.3. Canada Venous Thromboembolism Prophylaxis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By End Use

8. South America Venous Thromboembolism Prophylaxis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Venous Thromboembolism Prophylaxis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End Use
  • 8.3.2. Argentina Venous Thromboembolism Prophylaxis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End Use
  • 8.3.3. Colombia Venous Thromboembolism Prophylaxis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End Use

9. Middle East and Africa Venous Thromboembolism Prophylaxis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Venous Thromboembolism Prophylaxis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End Use
  • 9.3.2. Saudi Arabia Venous Thromboembolism Prophylaxis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End Use
  • 9.3.3. UAE Venous Thromboembolism Prophylaxis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End Use

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Venous Thromboembolism Prophylaxis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Arjo
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Encompass Group
• 14.3. Argon Medical Devices
• 14.4. MEGO AFEK
• 14.5. Zenith Technical Innovations
• 14.6. Cook Medical
• 14.7. Bio Compression Systems
• 14.8. ThermoTek USA
• 14.9. Boston Scientific Corporation
• 14.10.Cardinal Health (Medtronic)

15. Strategic Recommendations

16. About Us & Disclaimer